Tiffany Shih consults on life sciences and healthcare litigation and regulatory investigations. Dr. Shih works with academic experts and attorneys and leads large teams to perform complex economic analyses on antitrust, product misrepresentation, reimbursement, and breach of contract matters in these industries.
Dr. Shih’s experience includes:
Antitrust litigation and merger investigations
- Investigating allegations of anticompetitive delay of generic entry, including alleged product hopping and reverse payments matters, such as In re Novartis and Par Antitrust Litigation
- Examining class certification issues in end-payor and direct purchaser class actions
- Estimating competitive effects of vertical mergers in the health insurance industry, including in the $67 billion vertical merger between health insurer Cigna and pharmacy benefit manager Express Scripts and in United States et al. v. UnitedHealth Group Incorporated et al.
- Analyzing allegations of price fixing among generic drug manufacturers
Product misrepresentation and product liability matters
- Assessing the impact of pharmaceutical marketing on prescribers’ behavior and prescription drug sales
- Analyzing pharmaceutical companies’ drug development decisions
- Examining damages in consumer personal injury matters
- Analyzing consumer class certification issues in product liability matters in the pharmaceutical industry
Reimbursement disputes
- Evaluating economic issues related to risk-adjusted payments to Medicare Advantage insurers
Contract disputes
- Addressing breach of contract issues related to pharmaceutical R&D and licensing agreements
Dr. Shih has published articles on healthcare and life sciences topics in medical and economics journals. In her research, Dr. Shih has addressed how money flows through the pharmaceutical distribution system, the economic impacts of biologic drugs policies, and the economic costs of disease.
Prior to joining Cornerstone Research, Dr. Shih worked at Precision Health Economics, where she provided business consulting services to major pharmaceutical companies.
|
|
|
